Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 +0.38%95 3-Year RORE % is 14.17 as of Mar. 2026. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$30.01 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 603 Healthcare Providers & Services companies, Raia Drogasil ranks better than 64.51% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Raia Drogasil's 3-Year RORE % for the quarter that ended in Mar. 2026 was 14.17%.
The industry rank for Raia Drogasil's 3-Year RORE % or its related term are showing as below:
BSP:RADL3's 3-Year RORE % is ranked better than 64.51% of 603
companies
in the Healthcare Providers & Services industry
Industry Median: 0.07
vs BSP:RADL3: 14.17
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Raia Drogasil 3-Year RORE % Related Terms
Raia Drogasil 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Raia Drogasil (BSP:RADL3) has a 3-Year RORE % of 14.17 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Raia Drogasil and its competitors. According to the industry distribution chart, Raia Drogasil ranks #214 out of 603 companies in the Healthcare Providers & Services industry, placing it in the top 35.5%.
Is Raia Drogasil's 3-Year RORE % too high?
Raia Drogasil's current 3-Year RORE % is 14.17. The Healthcare Providers & Services industry median 3-Year RORE % is 0.07. Raia Drogasil's value of 14.17 is 20142.9% above this industry median. Based on the distribution chart, Raia Drogasil ranks #214 out of 603 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #214 out of 603 companies for 3-Year RORE %. This puts Raia Drogasil in the upper half of its industry. The industry median 3-Year RORE % is 0.07. Raia Drogasil's value of 14.17 is 20142.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.07, based on 603 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current 3-Year RORE % of 14.17 is 20142.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current 3-Year RORE % is 14.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.01, compared to a current price of R$18.67 — trading 37.8% below its estimated fair value. The current 3-Year RORE % is 14.17 and 20142.9% above the Healthcare Providers & Services industry median of 0.07. Raia Drogasil's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 3-Year RORE % is 14.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.67 is trading 37.8% below its estimated GF Value™ of R$30.01.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
3-Year RORE %: 14.17
GF Value™: R$30.01 vs. price of R$18.67 (37.8% below fair value)
Industry Position: 20142.9% above the Healthcare Providers & Services median (#214 of 603)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
